1Stanley WC. Changes in cardiac metabolism: a critical step from stable angina to ischemic cardiomyopathy. Eur Heart J Supplements,2001,3 ( Suppl 0) : 02-07.
2Kantor PF, Lucien A, Kozak R, et aL The anfianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res, 2000, 86:580-588.
3Renaud JF. Internal pH, Na^+ , and Ca^++ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther,1988,1:677-686.
4Schiller NB, Shah PM, Crawford M, et aL Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of two-dimensional Echocardiograms. J Am Soc Echocardiogr, 1989, 2:358-367.
5Aussedat J, Ray A, Kay L, et aL Improvement of long-term preservation of isolated arrested rat heart: beneficial effect of the antiischemic agent trimetazidine. J Cardiovasc Pharmacol, 1993,21 :128-135.
6Brottier L, Baaxt JL, Combe C, et aL Therapeutic value of a cardioprotective agent in patients with severe isehemic cardiomyopathy. Eur Heart J, 1990, 11:207-212.
7Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischemic cardiomyopathy. Eur Heart J, 2001, 22:2164-2170.
